Sunit Talapatra Bio

Dr. Sunit Talapatra’s practice focuses on the intellectual property needs of diverse technology clients spanning pharmaceuticals, diagnostics, agriculture, food and nutrition, and medical devices. He also has a unique perspective on European companies with ties to the United States, having lived in the Netherlands and frequently returning to the continent. He is a partner in the firm’s Chemical, Biotechnology & Pharmaceutical, and Private Equity & Venture Capital Practices as well as the Health Care & Life Sciences Sector. In addition to patent counseling and prosecution matters, Sunit has argued several cases before the United States Patent Trial and Appeal Board, notably orchestrating a successful defense in the “1st-Ever” Pharma AIA Ruling (Amneal Pharma Inc v. Supernus Pharma Inc.). Some of his exemplary patent cases include Chatterjee v. Tabor (interference proceeding re DNA polymerase); Keygene NV v. Floragenex, Inc. (patent infringement action); and Biota Scientific Ltd. v. Kappos (appeal of USPTO decision re obviousness of pharmaceutical formulation).